New York, NY (April 6, 2011) – Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have been selected to conduct a Phase I clinical research study of an investigational medication in patients with Chronic Obstructive Pulmonary Disease (COPD).
This is Clinilabs’ third clinical trial examining drug effects in patients with COPD. “As a specialty CRO, it is exciting to grow our franchise in respiratory disorders as we expand our expertise to an ever wider range of conditions” states Barbara Smallwood, Vice President of Business Development at Clinilabs.
Enrollment for this study is expected to begin in April 2011. We welcome referrals from physicians and other healthcare professionals. Individuals in the New York City Metro area who have been diagnosed with COPD can contact our call center at 212-994-4567 to prequalify. Additional information also may be found by visiting www.clinilabs.com/COPD.
About Clinilabs Inc.
Clinilabs is a contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies – services that can be scaled as needed to meet the requirements of any clinical development program. For more information, please visit www.clinilabs.com.
For more information or to schedule an interview, please contact Hannah D’Aoust at 646.215.6411 or e-mail hdaoust@clinilabs.com
